RadNet, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDNT research report →
Range $65 – $95
Price Chart
About the company
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures.
- CEO
- Howard G. Berger
- IPO
- 1997
- Employees
- 9,060
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on RDNT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.49B
- P/E
- -241.52
- Fwd P/E
- 119.31
- PEG
- 3.64
- P/S
- 2.30
- P/B
- 4.83
- EV/EBITDA
- 23.37
- Div Yield
- 0.00%
- Gross Margin
- 9.79%
- Op Margin
- 3.71%
- Net Margin
- -0.94%
- ROE
- -2.04%
- ROIC
- 1.40%
Latest fiscal year · YoY change
- Revenue
- $2.04B+11.5%
- Gross Profit
- $90.80M-63.5%
- Op Income
- $90.80M
- Net Income
- $-18,652,000-767.8%
- EPS
- $-0.25-754.5%
- OCF Growth
- +28.2%
- FCF Growth
- +90.4%
- 52W High
- $85.84
- 52W Low
- $50.82
- 50D MA
- $72.83
- 200D MA
- $65.44
- Beta
- 1.40
- RSI (14)
- 39
- Avg Volume
- 688.84K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
RadNet posted record Q3 revenue and EBITDA, raised full-year guidance again, and highlighted accelerating demand for advanced imaging plus a faster-than-expected Digital Health ramp.· November 9, 2026
- Q3 total company revenue was $638.3 million, up 22.1% year over year, and adjusted EBITDA was $105 million, up 23.8%, both quarterly records.
- Imaging Center volumes rose 19.9% overall and 8.9% on a same-center basis, with advanced imaging mix shifting higher and segment adjusted EBITDA up 25.3% to $102 million.
- Digital Health delivered record new business, with approximately $71 million of total contract value signed in Q3 and ARR reaching $112.6 million, up 67% year over year.
- Management raised 2026 guidance again for Imaging Center revenue, adjusted EBITDA and free cash flow, and lifted Digital Health adjusted EBITDA guidance while reaffirming revenue.
- RadNet ended the quarter with $750.6 million of cash and net debt to adjusted EBITDA of 1.66x, preserving flexibility for growth investments and M&A.
Total company revenue was $638.3 million in Q3 2026, up 22.1% from $522.9 million last year, and total company adjusted EBITDA was $105 million, up 23.8% from $84.9 million. Adjusted diluted EPS was $0.30 versus $0.24 a year ago. Imaging Center segment adjusted EBITDA was $102 million, up 25.3%, while Digital Health segment adjusted EBITDA was $3 million versus $3.5 million last year. For 2026, Imaging Center net revenue guidance was raised to $2.385 billion to $2.435 billion, adjusted EBITDA to $350 million to $363 million, capex to $170 million to $180 million, and free cash flow to $120 million to $130 million. Digital Health reaffirmed revenue guidance of $135 million to $145 million and raised adjusted EBITDA before noncapitalized R&D to $11 million to $13 million. Management also said Digital Health is on track for more than $140 million of ARR by year-end and expects Q4 Digital Health revenue to grow about 20% sequentially. They estimated the 2027 Medicare final rule will reduce RadNet revenue by about $5 million, and said ONRAD is expected to add $190 million to $200 million of revenue and $60 million to $65 million of adjusted EBITDA in its first year after closing.
Howard Berger framed the quarter as evidence that RadNet is building a broader healthcare platform around advanced imaging, AI, and hospital-based services. He emphasized that AI and new imaging technology are expanding capacity, improving early diagnosis, and helping the company address radiologist and technologist shortages. His tone was highly strategic and optimistic, with repeated references to long-term transformation, not just quarterly execution.
Mark Stolper focused on the financial beat, noting record revenue and EBITDA, adjusted diluted EPS of $0.30, and strong liquidity with $750.6 million of cash plus full availability under the $282 million revolver. He said DSO remained at 31 days and net debt was $590.2 million, with leverage at 1.66x. On guidance, he detailed higher 2026 targets for Imaging Center revenue, EBITDA, capex, and free cash flow, and said Digital Health EBITDA guidance increased due to effective expense management and faster integration of acquired operations. He also quantified the 2027 Medicare final-rule impact at about $5 million and explained ONRAD’s purchase terms as $350 million of cash plus 5 million shares, with an earn-out tied to EBITDA above $56 million.
Analysts asked whether advanced imaging strength can continue, and management said demand is being supported by aging demographics, faster scanners, PET/CT technology upgrades, CT coronary angiography, and increased breast MRI, with growth now constrained more by capacity than demand. On TechLive and operational efficiency, management said remote technologists are helping reduce closure hours and that about 13% of MRI exams were completed with remote technologists in Q3, with further rollout ahead. Analysts also pressed on Digital Health visibility; management said the ARR base is already underpinned to just above $140 million and described Q4 as supported by three revenue buckets: external customer deployments, RadNet rollouts, and some perpetual licenses. Questions on ONRAD centered on productivity and deal structure; management said the acquisition should let RadNet extend its AI and workflow tools into hospitals and could accelerate an integrated, system-wide offering, though broad enterprise rollout will be a heavy lift.
The bullish case from this call is that RadNet is showing leverage from both its imaging core and its Digital Health platform. Advanced imaging demand, new center openings, and capacity initiatives are driving strong same-center growth, while Digital Health is signing larger contracts, expanding ARR, and moving toward a much bigger Q4 and 2027 contribution. The ONRAD acquisition also appears to broaden the addressable market into hospital radiology with high-margin, capital-light services.
The main risks are execution-heavy: RadNet still has labor shortages, implementation capacity constraints, and a large amount of operational change to deliver across imaging centers, Digital Health, and ONRAD. Management also flagged a roughly $5 million 2027 Medicare headwind, and the Digital Health segment remains in an investment phase with margin still below prior-year levels. ONRAD integration and the promised productivity gains are not immediate, and management acknowledged the enterprise rollout is a heavy lift that will take time to scale.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.6%
- Shares Outstanding
- 78.77M
- Float Shares
- 65.88M
of shares held by institutions
337 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.02M | ▲ 62.98K |
| Vanguard Group Inc | 7.46M | ▼ 20.77K |
| Price T Rowe Associates Inc | 4.94M | ▲ 440.20K |
| Rtw Investments, LP | 4.63M | ▼ 216.26K |
| Vanguard Portfolio Management LLC | 4.00M | ▼ 66.11K |
| Vanguard Capital Management LLC | 3.19M | ▲ 828 |
| Beck Mack & Oliver LLC | 3.00M | ▼ 165.84K |
| State Street Corp | 2.89M | ▲ 51.63K |
| Invesco Ltd. | 1.85M | ▲ 213.63K |
| Geode Capital Management, LLC | 1.85M | ▼ 13.27K |
| Clearbridge Investments, LLC | 1.65M | ▲ 104.58K |
| American Century Companies Inc | 1.65M | ▲ 27.01K |
Held by 426 ETFs
Biggest fund positions in RDNT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Patel Mital | sell | 44,661 |
| Nov 12, 26 | Patel Mital | other | 640 |
| Jun 18, 26 | SWARTZ DAVID L | sell | 2,699 |
| Jun 16, 26 | Wesdorp Cornelis | sell | 4,750 |
| Jun 16, 26 | Berger Howard G | other | 90 |
| Jun 15, 26 | Forthuber Stephen M | sell | 24,214 |
| Jun 15, 26 | Forthuber Stephen M | sell | 19,853 |
| Jun 2, 26 | SWARTZ DAVID L | other | 2,946 |
| Jun 2, 26 | SPURLOCK GREGORY E. | other | 2,946 |
| Jun 2, 26 | Jacobs Laura Pastre | other | 2,946 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RDNT coverage
Recent articles, reports, and earnings notes.
No research on RDNT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RDNT report →DeepHealth to Present Recent Clinical Evidence Demonstrating the Breadth and Impact of Its AI Portfolio at RSNA 2026
globenewswire.com · Nov 19
Wall Street Analysts Believe RadNet (RDNT) Could Rally 25.13%: Here's is How to Trade
zacks.com · Nov 18
AlphaCore Capital LLC Makes New Investment in RadNet, Inc. $RDNT
defenseworld.net · Nov 14
Why RadNet (RDNT) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 13
RadNet's Imaging Growth Can Fund DeepHealth's Hospital Rollout
seekingalpha.com · Nov 12
RadNet: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 10
RadNet: A 'Buy' On Sizable Q3 Beat And Value-Generating M&A
seekingalpha.com · Nov 10
RadNet, Inc. (RDNT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.